Johnson & Johnson Bets Big on Next-Gen Growth

Johnson & Johnson ((JNJ)) has held its Q1 earnings call. Read on for the main highlights of the call.

Johnson & Johnson’s latest earnings call struck an overall optimistic tone, with management leaning on strong operational sales growth, high‑velocity oncology and immunology drugs, and a robust launch pipeline. While profitability metrics were pressured by the steep STELARA decline and heavy investment in new products, executives repeatedly framed 2026 as an investment year that sets up faster growth and margin recovery toward decade end.

Broad-Based Sales Growth Despite STELARA Drag

Johnson & Johnson reported Q1 2026 worldwide sales of $24.1 billion, translating to operational growth of 6.4% and pointing to about $100.8 billion of full‑year revenue at the midpoint of guidance. Stripping out the roughly 540‑basis‑point headwind from the sharp STELARA decline, management emphasized that underlying company growth was solidly in the double digits, led by 8.3% in the U.S. and 3.9% ex‑U.S.

Upgraded Full-Year Outlook Signals Confidence

The company raised its 2026 operational sales outlook to 5.9%–6.9%, implying 6.4% growth at the midpoint and 6.5%–7.5% on a reported basis, helped by a 53rd week. Adjusted operational EPS guidance was nudged higher by $0.02 to a range of $11.30–$11.50, with the midpoint up 5.7%, while reported adjusted EPS is now expected to land around $11.55, an increase of 7.1%.

Innovative Medicine Delivers Through Product Transitions

Innovative Medicine generated $15.4 billion in sales, up 7.4% operationally despite a daunting 920‑basis‑point drag from STELARA erosion. Management highlighted that ten brands posted double‑digit gains and that 28 platforms or products already produce at least $1 billion annually, underlining a diversified revenue base supported by fresh launches such as ICOTYDE and new subcutaneous oncology formulations.

Oncology and Immunology Stars Fuel Growth

High‑growth therapies again stole the show, with DARZALEX delivering nearly $4.0 billion in sales, up about 18%, and CARVYKTI surging 57.4% to roughly $600 million. Additional momentum came from TECVAYLI, TALVEY, RYBREVANT with LAZCLUZE, ERLEADA and the immunology workhorse TREMFYA, which grew about 63.8% and is now projected by management to ultimately surpass $10 billion in peak annual revenue.

ICOTYDE Launch Points to a New Psoriasis Era

The oral IL‑23 peptide ICOTYDE, approved for first‑line plaque psoriasis, is off to a rapid commercial start that management described as market‑expanding. With a day‑one launch, the first patient was on therapy within 24 hours, and early metrics showed about 1,500 prescriptions and more than 1,000 unique prescribers, reinforcing expectations that ICOTYDE could ultimately become a multibillion‑dollar franchise.

MedTech Grows on Electrophysiology and Structural Heart

MedTech delivered $8.6 billion in sales, representing 4.6% operational growth and led by high‑value niches rather than broad surgical strength. Electrophysiology climbed 9.5% helped by new VARIPULSE launches, while Abiomed advanced 14.4% on stronger Impella use and Shockwave grew 18.1% as intravascular lithotripsy adoption continued to expand, backed by a string of device approvals and positive data readouts.

INLEXZO Gains Traction with Key Reimbursement Win

New device INLEXZO posted just over $30 million in Q1 sales but appears poised for acceleration after securing a permanent J‑code in early April. Management noted that roughly one in five eligible patients started on INLEXZO during Q1, and after the new reimbursement took effect, new patient insertions jumped about 50% in the first week and roughly 90% in the second week.

Solid Balance Sheet, Strong Cash Generation and Dividend Lift

The company ended the quarter with about $22 billion of cash and marketable securities against $55 billion of debt, leaving net debt around $33 billion. Free cash flow was $1.5 billion in the quarter, with management reiterating expectations for roughly $21 billion for the full year, and the board approved a 3.1% dividend increase to $5.36 annually, marking the 64th consecutive year of dividend growth.

Scaling U.S. Manufacturing and R&D Investment

Johnson & Johnson underscored its long‑term commitment to domestic production and innovation through a $55 billion U.S. investment plan extending through early 2029. About $12 billion is expected to be deployed by the end of 2025, roughly 22% of the target, with substantial additional capital earmarked for manufacturing, technology and R&D projects in 2026 and beyond.

Rich Pipeline and 2026 Catalysts in Focus

Management laid out a busy 2026 pipeline agenda, citing regulatory and data milestones across oncology, immunology and neuroscience as key growth drivers. Among the highlights are additional TREMFYA indications, further ERLEADA readouts, expansion for INLEXZO, important inflammatory bowel disease and bipolar mania data, and several MedTech submissions including OTTAVA and advanced electrophysiology systems.

STELARA Decline Creates a Heavy Growth Headwind

The biggest drag on reported results came from STELARA, whose sales plunged 61.7% year over year as biosimilars, newer drug classes and an unfavorable patient mix took hold. Management quantified STELARA’s impact as about a 540‑basis‑point headwind to overall company growth and an even larger 920‑basis‑point obstacle within the Innovative Medicine segment, complicating year‑over‑year comparisons.

GAAP EPS Hit by Comparability and Special Items

GAAP net earnings fell to $5.2 billion, translating into diluted EPS of $2.14 compared with $4.54 a year earlier, a drop driven heavily by lapping prior one‑time benefits. On an adjusted basis, net earnings were $6.6 billion and EPS came in at $2.70, down 1.4% and 2.5% respectively, signaling that while core operations are growing, reported earnings still face visible pressure and volatility.

Margin Deleveraging Reflects Heavy Launch Spending

Profitability compressed across the portfolio, with Innovative Medicine’s adjusted margin slipping from 42.5% to 39.7% as launch costs and mix weighed on returns. MedTech’s margin fell from 25.9% to 22.3%, while enterprise adjusted income before tax margin declined from 36.6% to 32.5%, highlighting the near‑term trade‑off between funding growth assets and maintaining peak margin levels.

Earnings Distorted by Prior-Year One-Time Benefits

The company’s other income and expense line swung from $7.3 billion of income in the prior‑year quarter to a net expense of $294 million, largely because of a roughly $7 billion reserve reversal booked last year. Management stressed that this significant one‑off item is creating noisy comparisons and masking underlying operating performance trends when investors look at year‑on‑year EPS.

Softer Q1 Free Cash Flow but Full-Year Intact

First‑quarter free cash flow of about $1.5 billion points to a weaker run‑rate than implied by the full‑year $21 billion goal, as timing changes in U.S. rebate payments and higher domestic capital expenditures weighed on cash conversion. Executives maintained that these effects are temporary and that free cash flow should ramp over the remainder of 2026 as working capital normalizes and new launches scale.

MedTech Faces Competitive and Pricing Pressures

Not all MedTech categories kept pace, with the Surgery franchise growing only 1.2% amid a planned transformation program and rising competition in energy devices and endocutters, as well as volume‑based procurement in China. U.S. surgical vision also encountered tougher competition, causing near‑term softness even as global demand for premium intraocular lenses remained healthy.

Higher Interest Burden Weighs on Bottom Line

The interest line shifted from a net income contribution of $128 million in Q1 2025 to a net expense of $43 million in Q1 2026, as average cash balances declined and debt levels increased. This change added another layer of pressure to reported earnings and underscores how balance sheet mix can influence net income even when operating trends are positive.

Execution Risks Around Spending and China Pricing

Management acknowledged that heavier SG&A spending, which deleveraged by about 180 basis points, and stepped‑up launch investments will keep margins under pressure in the first half. They also flagged potential second‑half volume‑based procurement impacts in China for electrophysiology products, calling for disciplined execution and cost control to offset these external and self‑inflicted headwinds.

Guidance Underscores Growth Ambition and Margin Recovery

Forward‑looking guidance remains constructive, with the company raising sales expectations and slightly lifting EPS while reiterating a target for at least 50 basis points of adjusted pretax operating margin improvement in 2026. Management continues to project roughly $21 billion in free cash flow, maintain assumptions for interest and tax, and align capital priorities around funding a $55 billion U.S. investment plan and growing the dividend alongside earnings.

The earnings call painted a picture of a company in transition, absorbing the impact of a fading blockbuster and higher spending while leaning into a new generation of growth drivers. For investors, the main takeaways are resilient top‑line momentum, a deep late‑stage pipeline and clear confidence in long‑term double‑digit growth, offset by near‑term earnings noise, thinner margins and the need for flawless execution on launches and cost discipline.